@article{61cd0eb3013c406d9fa79e35ba016358,
title = "Nivo-lution in mesothelioma",
abstract = "The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.",
author = "Mansfield, {Aaron S.} and Zauderer, {Marjorie G.}",
note = "Funding Information: A.S. Mansfield reports receiving commercial research grants from Novartis, and is a consultant/advisory board member for AbbVie, Bristol-Myers Squibb, and Genentech. M.G. Zauderer reports receiving commercial research grants from Curis, Bristol-Myers Squibb, Epizyme, MedImmune, Polaris, Sellas Life Sciences, and Millenium, other commercial research support from Roche, and is a consultant/advisory board member for Novocure, Aldeyra, and Epizyme. No other potential conflicts of interest were disclosed by the other authors. Funding Information: A.S. Mansfield was supported by NIH award P30CA015083.",
year = "2019",
month = sep,
day = "15",
doi = "10.1158/1078-0432.CCR-19-1836",
language = "English (US)",
volume = "25",
pages = "5438--5440",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",
}